One case of rash caused by chiglitazar sodium tablets

doi:10.19803/j.1672-8629.20250774

Abstract

Abstract: Objective To investigate the clinical characteristics and potential immunologic mechanisms associated with rashes induced by chiglitazar sodium tablets in order to provide a reference for safe medication. Methods The clinical data of a patient who had developed a rash following the administration of chiglitazar sodium was retrospectively analyzed. Causality was evaluated using the Naranjo Adverse Drug Reaction Probability Scale, and related literature was reviewed to explore possible immune mechanisms and treatment strategies. Results The patient presented with a rash the day chiglitazar sodium tablets were administrated, which progressed to a generalized rash across the body within six days. Symptoms were resolved within 48 hours of drug discontinuation. The Naranjo score was 6, indicating a “probable” association with the drug. Literature suggested that this type of rash might be linked to immune mechanisms. Treatment involved drug discontinuation, and the prognosis was favorable following symptomatic management. Conclusion Chiglitazar sodium tablets carry the risk of inducing rashes, so enhanced clinical monitoring and early identification are recommended. Upon the onset of a rash, immediate discontinuation of the drug and prompt intervention are essential to safe medication.

Key words: Chiglitazar Sodium Tablets, Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, Type 2 Diabetes, Rash, Adverse Drug Reaction

CLC Number:

Lin Liping, Chen Yan, Jia Xueling. One case of rash caused by chiglitazar sodium tablets[J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 944-947.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250774

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I8/944

References

[1] Li Yiqi, Gao Jianmei, Gong Qihai.Research progress of drugs targeting peroxisome proliferator-activated receptors for type 2 diabetes mellitus[J]. Journal of Zunyi Medical University(遵义医科大学学报), 2023, 46(2): 214-220.
[2] Chengdu Weixin Pharmaceutical Co., Ltd. Drug Instructions for Chiglitazar Sodium Tablets[EB/OL]. (2024-12-03)[2025-12-08]. https://drugs.dxy.cn/pc/drug/pAeeY54ueJkGHQDzpGeb4AQ?ky=%E8%A5%BF%E6%A0%BC%E5%88%97%E4%BB%96%E9%92%A0.
[3] Vetter Pharma-Fertigung GmbH & Co.KG. Drug Instructions for Dulaglutide Injection[EB/OL]. (2023-12-06) [2025-12-08]. https://drugs.dxy.cn/pc/drug/pfDyp7Swf4q46wUvdvgZhSg?ky=%E5%BA%A6%E6%8B%89%E7%B3%96%E8%82%BD%E6%B3%A8%E5%B0%84%E6%B6%B2.
[4] Janssen-Cilag S.p.A. Drug Instructions for Canagliflozin Tablets[EB/OL]. (2024-12-12)[2025-12-08]. https://drugs.dxy.cn/pc/drug/pqLQbPVAODHsrUXr9k17hCg?ky=%E6%80%A1%E5%8F%AF%E5%AE%89.
[5] Center for Drug Evaluation, National Medical Products Administration. Technical Guideline for the Assessment of Causality in Adverse Events in Drug Clinical Trials (Trial Implementation)[EB/OL]. (2024-06-14)[2025-11-29]. https://www.cde.org.cn/main/news/viewInfoCommon/0a5ae4924881321c07cce100e99f2a5c.
[6] Lyu Xiaofeng, Gao Yongyi, Zhu Lyuyun, et al.Efficacy and safety of chiglitazar sodium in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-controlled clinical trial[J]. Chinese Journal of Diabetes Mellitus(中华糖尿病杂志), 2019, 11(5): 334-340.
[7] Jia W P, Ma J H, Miao H, et al.Chiglitazar monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomized, double-blind, phase 3 trial (CMAS)[J]. Science Bulletin, 2021, 66(15): 1581-1590.
[8] National Medical Products Administration. Measures for the Repor-ting and Monitoring of Adverse Drug Reactions[EB/OL]. (2011-05-04)[2025-12-08]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110504120001414.html.
[9] Naranjo C A, Busto U, Sellers E M, et al.A method for estimating the probability of adverse drug reactions[J]. Clinical Pharmacology and Therapeutics, 1981, 30(2): 239-245.
[10] Luo Wei, Lan Mingxiong, Ma Aiwen, et al.Correlation between vitamin AD drops and infantile eczema based on the Naranjo adverse drug reaction assessment scale[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2025, 31(8): 46-49.
[11] Wu Yatong, Wang Feifei, Zang Xiaohui, et al.Fenofibrate-induced photosensitive dermatitis: a case report[J]. Journal of Clinical Derma-tology(临床皮肤科杂志), 2017, 46(9): 663.
[12] Cheng Kai, Xu Ting, Tang Yao, et al.Analysis of adverse drug reactions induced by fenofibrate[J]. West China Medical Journal(华西医学), 2010, 25(8): 1536-1538.
[13] Xie Fujun, Chen Yanqiu.Rosiglitazone-associated exfoliative kerato-lysis[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2009, 11(1): 50-51.
[14] Zhao Jingqi, He Gang.A case of exfoliative dermatitis induced by rosiglitazone maleate tablets[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2013, 10(2): 123.
[15] Huang Shuhua, Chen Zhumei, Zeng Qingfan.Effect of PPARγ activation on perioperative neurocognitive disorders by inhibiting central nervousinflammation in aged rats[J]. Shanxi Medical Journal(山西医药杂志), 2025, 54(21): 1603-1607.
[16] Wang Yu.Role and mechanism of peroxisome proliferator-activated receptorα in diabetic nephropathy[D]. Taiyuan: Shanxi Medical University, 2025.
[17] Zhou Jing, Luo Li, Zhu Junyu, et al.Mechanism and therapeutic implications of peroxisome proliferator-activated receptorα in kidney injury[J]. Chinese Critical Care Medicine(中华危重病急救医学), 2025, 37(7): 693-697.
[18] An J, Nakajima T, Kuba K, et al.Losartan inhibits LPS-induced inflammatory signaling through a PPARγ-dependent mechanism in human THP-1 macrophages[J]. Hypertension Research, 2010, 33(8): 831-835.